---
title: 'Perispinal Etanercept to improve STroke Outcomes (PESTO): Protocol for a multicenter,
  international, randomized placebo-controlled trial'
date: '2024-04-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38676623/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240428181100&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'RATIONALE: A large proportion of stroke survivors will have long-lasting,
  debilitating neurological impairments, yet few efficacious medical treatment options
  are available. Etanercept inhibits binding of tumor necrosis factor to its receptor
  and is used in the treatment of inflammatory conditions. Perispinal subcutaneous
  injection followed by a supine, head down position may bypass the blood brain barrier.
  In observational studies and one small randomized controlled trial the majority
  ...'
disable_comments: true
---
RATIONALE: A large proportion of stroke survivors will have long-lasting, debilitating neurological impairments, yet few efficacious medical treatment options are available. Etanercept inhibits binding of tumor necrosis factor to its receptor and is used in the treatment of inflammatory conditions. Perispinal subcutaneous injection followed by a supine, head down position may bypass the blood brain barrier. In observational studies and one small randomized controlled trial the majority ...